Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy
Jazyk angličtina Země Velká Británie, Anglie Médium print
Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie
PubMed
15613141
DOI
10.1111/j.1468-1331.2004.00966.x
PII: ENE966
Knihovny.cz E-zdroje
- MeSH
- agonisté dopaminu terapeutické užití MeSH
- analýza rozptylu MeSH
- deprese komplikace farmakoterapie psychologie MeSH
- kognitivní poruchy komplikace farmakoterapie psychologie MeSH
- kombinovaná farmakoterapie MeSH
- levodopa terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- neparametrická statistika MeSH
- Parkinsonova nemoc komplikace farmakoterapie psychologie MeSH
- prospektivní studie MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
- Názvy látek
- agonisté dopaminu MeSH
- levodopa MeSH
In a randomized prospective multi-centre study, we evaluated the cognitive performances of a group of 41 non-demented patients, all with advanced Parkinson's disease (PD) and a current depressive episode, in whom the effects of pramipexole (PPX) and pergolide (PRG) in an add-on to l-dopa therapy were also studied and published with regard to motor symptoms of PD, motor complications and depression. The Trail Making Test, the Stroop test and four subtests (arithmetic, picture completion, digit symbols and similarities) of the Wechsler Adult Intelligence Scale-Revised were performed prior to and 8 months after the administration of either PPX or PRG. We found no statistically significant difference between the two tested drugs or between the first and the last visit in any of the above-listed neuropsychological tests. All patients' motor outcomes significantly improved and we conclusively demonstrated the anti-depressive effect of PPX. The dissociation of dopaminomimetic effects on the different tested domains indicates that there are different pathological mechanisms of cognitive, motor and affective disturbances in advanced PD patients. In our non-demented group of fluctuating depressed PD subjects, both PPX and PRG administration in combination with l-dopa were safe in terms of the effect on cognitive performance.
Citace poskytuje Crossref.org
Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study
The reduction of hippocampal volume in Parkinson's disease
